Eli Lilly changes outcome goals in Alzheimer's drug study

Eli Lilly changes outcome goals in Alzheimer's drug study


" Eli Lilly says it's changed the outcome goals for a late-stage patient study of its closely watched experimental drug for Alzheimer's disease, solanezumab. The Expedition3 trial had two primary outcome measures: changes in participants' cognition and their daily function.



from Biotech News